UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications

Daniel Cabrera, Juan Pablo Arab, Marco Arrese*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

52 Scopus citations

Abstract

Bile acids (BAs) are key molecules in generating bile flow, which is an essential function of the liver. In the last decades, there have been great advances in the understanding of BA physiology, and new insights have emerged regarding the role of BAs in determining cell damage and death in several liver diseases. This new knowledge has helped to better delineate the pathophysiology of cholestasis and the adaptive responses of hepatocytes to cholestatic liver injury as well as of the mechanisms of injury of biliary epithelia. In this context, therapeutic approaches for liver diseases using hydrophilic BA (i.e., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the present review, we summarize current experimental and clinical data regarding these BAs and its role in the treatment of certain liver diseases.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer New York LLC
Pages237-264
Number of pages28
DOIs
StatePublished - 2019
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume256
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Bibliographical note

Publisher Copyright:
© 2019, Springer Nature Switzerland AG.

Keywords

  • Bile acids
  • Bile flow
  • Cell injury
  • Cholestasis
  • Inflammation
  • Liver diseases
  • Signaling

Fingerprint

Dive into the research topics of 'UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications'. Together they form a unique fingerprint.

Cite this